DOCSLIB.ORG

Curriculum Vitae Gabor Istvan Keitner, MD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae Gabor Istvan Keitner, MD 2935May 2018 Curriculum Vitae Gabor Istvan Keitner, MD Business Address Rhode Island Hospital Potter Building, 3rd Floor 593 Eddy Street Providence, RI 02903 Business TEL. Number (401) 444-3967 Business FAX. Number (401) 444-3298 Email: [email protected] EDUCATION Undergraduate Bishop's University, Honors Psychology, B.A. 1968 Bishop's Associate Award, 1967-1968 The University Prize in Psychology, Bishop's University, 1968 Medical School Queen's University, 1969-1973, M.D. 1973 Social Science Prize, Queen's Medical Review, 1970 The Alice Pierce Waddington Scholarship, Queen's University, 1972 The Victor Lyall Goodwill Memorial Essay Prize, Queen's University, 1972 The Professor's Prize in Psychiatry, Queen's University, 1973 POSTGRADUATE TRAINING Residency McMaster University Medical Centre, Hamilton, Ontario. Straight (6 months - Acute Inpatient Psychiatry and 6 months - Family Medicine), July 1974-June 1975 McMaster University Medical Centre, Hamilton, Ontario. Resident II, Consultation and Outpatient Psychiatry, July 1975-June 1976 Chedoke Hospital, Hamilton, Ontario. Resident III, Child Psychiatry, July 1976-December 1976 McMaster University Medical Centre, Hamilton, Ontario. Resident III, Acute Inpatient Psychiatry, January 1977-March 1977; Neurology, April 1977-September 1977 Hamilton Psychiatric Hospital, Hamilton, Ontario Resident IV and Chief Resident, October 1977-June 1978 POST GRADUATE HONORS AND AWARDS Distinguished Life Fellow, American Psychiatric Association, 2011 Deans Excellence in Teaching Award, May 2010 Honorary Member of the Hungarian Psychiatric Association for Contribution to Hungarian and International Psychiatry, Jubilee Anniversary Meeting of the Hungarian Psychiatric Association, Budapest, January 2005. Dean’s Teaching Excellence Award, July 2001 Exemplary Psychiatrist Award, NAMI 1994, 1996 Outstanding Teaching Award in General Psychiatry 1996 – 1997. Brown University School of Medicine, Department of Psychiatry and Human Behavior. Master of Arts (ad eundem), Brown University, 1987 Outstanding Teaching Award in General Psychiatry 2013-2014. The Alpert Medical School of Brown University, Department of Psychiatry and Human Behavior. Psychiatry Residents’ Award for Outstanding Clinicians. 2016-2017 The Alpert Medical School of Brown University Department of Psychiatry and Human Behavior MILITARY SERVICE None PROFESSIONAL LICENSES AND CERTIFICATION License (M.D. 5632) - State of Rhode Island - 1980 Fellow - American Board of Psychiatry and Neurology – 1995 Distinguished Fellow – American Board of Psychiatry and Neurology - 2003 Diplomate - American Board of Psychiatry and Neurology (P), July 1980 Added Qualification in Geriatric Psychiatry, 1996 Fellow, Royal College of Physicians and Surgeons of Canada [F.R.C.P.(C)], January 10, 1979 General License, College of Physicians, and Surgeons of Ontario December 15, 1978 Licentiate of the Medical Council of Canada (L.M.C.C.), December 1978 ACADEMIC APPOINTMENTS Professor, Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, 1992 – to date Associate Professor, Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, 1986 - 1992 Assistant Professor, Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, 1980 - 1986 2 Lecturer, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, July 1978 - December 1979 HOSPITAL APPOINTMENTS Director,1973 Family Therapy/Research Program, Rhode Island Hospital. 2017- to date Senior Clinical Educator, Rhode Island Hospital, 2017 to date Associate Psychiatrist-In-Chief, Rhode Island Hospital, Providence, RI, March 1996 – 2017. Associate Psychiatrist-In-Chief, Miriam Hospital, Providence, RI 2011-2017. Director, Adult Psychiatry, Rhode Island Hospital, Providence, RI 1996 - to date. Director, Mood Disorders Program, Rhode Island Hospital, Providence, RI 1996 - to date Medical Director, Inpatient Services, Butler Hospital, RI, September 1993 – February 1996 Associate Medical Director, Inpatient Services, Butler Hospital, Providence, RI, September 990 – October 1993 Director, Inpatient Services, Butler Hospital, Providence, RI, September 1985 – October 1990 Unit Chief, Butler Hospital, Providence, RI, October 1980 – February 1996 Staff Psychiatrist, Hamilton Psychiatric Hospital, Hamilton, Ontario,, July 1978 - June 1979 Courtesy Staff, Chedoke-McMaster Hospital, Hamilton, Ontario, July 1978 - June 1979 Affiliate Staff, St. Joseph's Hospital, Hamilton, Ontario, July 1978 - June 1979 Director, Mood Disorders Program, Butler Hospital, Providence, RI, 1981 – 1996 Director, Inpatient Division Department of Psychiatry, Rhode Island Hospital, RI 1996 - to date OTHER APPOINTMENTS Clinical Competency Committee, Brown University Psychiatry Residency Program January 2018- Coordinator, Inpatient Chief Rounds, Butler Hospital, Providence, Rhode Island, October 1992 - 1996 3 Member, Task Force on Psychosocial Treatments of Bipolar Disorder, John D. and Catherine T. MacArthur Foundation Research Network on the Psychobiology of Depression and Other Affective Disorders. Director, Audiovisual Department, Butler Hospital, Providence, RI, 1980 - 1996 Director of Education, Butler Hospital, Providence, RI, 1980 - 1988 Coordinator of Clinical Clerkship, Brown University, Butler Hospital, Providence, RI, 1980 - 1985 Coordinator, Psychiatrist-in-Chief Rounds, Butler Hospital, Providence, RI, 1981 – 1988 REVIEWER The American Journal of Psychiatry Psychiatry Research Journal of Hospital and Community Psychiatry The Journal of Nervous and Mental Disease Psychosomatics Journal of Clinical Psychopharmacology Journal of Clinical Psychiatry The Journal of Neuropsychiatry and Clinical Neurosciences Member, Editorial Board, The Brown University Family Therapy Letter Family Process – Editorial Board Psychiatria Hungarica, Advisory Board South African Psychiatry Review, Advisory Board, 2003 HOSPITAL COMMITTEES Member, Medical Council, Butler Hospital, Providence, RI, 1988 - 1996 Member, Quality Assurance Committee, Butler Hospital, Providence, RI, 1988 - 1996 Member, Library Committee, Butler Hospital, Providence, RI, January 1981 – 1996 Behavioral Health Executive Committee, Lifespan, Providence, RI, 2000- to date Member, Department of Psychiatry and Human Behavior Leadership Council, Brown University, Providence, RI 2002 -to date Continuing Medical Education Committee, Rhode Island Hospital, Providence, RI 2005- Medical Executive Council, Rhode Island Hospital, Providence, RI 2012- to date Member, Board of Trustees, Lifespan Physician Group, Inc. Lifespan, Providence, RI July, 2013 - 4 UNIVERSITY COMMITTEES Department of Psychiatry and Human Behavior Leadership Committee, Brown University, Providence, RI 2007-to date Member, Residency Policy Advisory Committee, Department of Psychiatry, Brown University, Providence, RI, 1980 - to date Member, PIM Teaching Scholars Committee, Brown University, Providence, RI, 1991 - 1995 Member, Medical Committee on Academic Standing, Brown University, Providence, RI, October 1986 -1992. Member, Policy Management and Advisory Committee (PMAC), Department of Psychiatry and Human Behavior, Brown University, Providence, RI 1988- Member, Undergraduate Education Committee, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, January 1980 – 1985 MEMBERSHIP IN SOCIETIES Royal College of Physicians and Surgeons of Canada, 1979 American Psychiatric Association, 1980 - Rhode Island Psychiatric Society of the American Psychiatric Association, 1980 - American Orthopsychiatric Association, 1981 - 1984 American Family Therapy Association, 1984 - 1992 Association for Clinical Psychosocial Research, 1985 - 2006 Council Member 1994 - 2006 International Society of Psychoendocrinology, 1985 - 1995 International Family Therapy Association, 1987 - 1992 Treasurer 1987-1991 Society for Psychotherapy Research, 1991- Association of Family Psychiatrists 1992 – Board of Directors for the Association of Family Psychiatrists 2011 – Fellowship, American Psychiatric Association, 1994 Scientific Advisory Board of the National Depressive and Manic Depressive Association, 1997 - 2001 American Association for Geriatric Psychiatry, 1998 - American Psychopathological Association – Fellow, 1999 - 2005 International Society for Affective Disorders, 2002 - World Psychiatric Association, Chair, Section of Family Research and Intervention, 2002 – 2009 5 World Psychiatric Association, Life Emeritus Section Chair, Section of Family Research and Intervention, 2015 World Psychiatric Association, Member of Advisory Council to the Scientific Committee, 2003 American Society of Clinical Psychopharmacology 2016 PUBLICATION LIST ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS 1. Grof, P., Angst, J., Karasek, M. Keitner, G.I. Patient selection for long-term lithium treatment in clinical practice. Archives of General Psychiatry 36:894-897, 1979. 2. Grof, P., MacCrimmon, D.F., Smith, E.K.M., Daigle, L., Saxena, B., Varma, R., Grof, E., Keitner, G.I., Kenny, J. Long-term lithium treatment and the kidney: interim report on fifty patients. Canadian Journal of Psychiatry 25:535-544, 1980. 3. Keitner, G.I., Grof, P. Sexual and emotional intimacy between psychiatric inpatients: formulating a policy. Hospital and Community Psychiatry 32:188-193, 1981. 4. Keitner, G.I., Grof, P. The routine EEG - how is it used in clinical practice? Psychiatric Journal of the University of Ottawa Faculty of Medicine 6:144-148, 1981. 5. Haier, R.J., Keitner,
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Indole Derivatives Acting on Central Nervous System – Review
    J Pharm Sci Bioscientific Res. 2016 6(1):144-156 ISSN NO. 2271-3681 Indole Derivatives acting on Central Nervous System – Review Deweshri R. Kerzarea & Pramod B. Khedekar Computer Aided Drug Design Laboratory, Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Amravati Road, Nagpur 440 033, MS, India ABSTRACT: Indole represents one of the most important heterocyclic ring which provides privileged scaffolds in drug discovery. Indole derivatives and its pharmacological significance provides tremendous opportunities to discover novel drugs with different modes of action. There are also amazing numbers of indole containing drugs in the market as well as compounds in clinical evaluation. This review serves as a comprehensive overview of currently published indole containing central nervous system acting agents with the main objectives in comprehensive listings of indole containing central nervous system drugs on market or compounds in clinical evaluation and to focus on recent developments of indole derivatives which are currently evaluated in experimental studies and their central nervous system activities. KEYWORDS: Indole, anticonvulsant, antidepressant, antianxiety, sedative, hypnotic Article history: 1. INTRODUCTION Received 26 Oct, 2015 Accepted 8 Dec 2015 The name indole is portmanteau of the words indigo and oleum. Indole is an Available online 01 Jan 2016 aromatic heterocyclic organic compound. It has a bicyclic structure, consisting of a benzene ring and a pyrrole nucleus are fused in 2, 3 positions Citation: 1-3 of the pyrrole ring. Indole is non-basic nitrogenous compound. Indole Kerzarea D. R. & Khedekar P. B. Indole chemistry began to develop with the study of the dye indigo. The word Derivatives acting on Central Nervous Indole is coined from the word India, a blue dye imported from India known System – Review.
    [Show full text]
  • Mehta Hiren R Et Al. IRJP 2011, 2 (12), 132-138
    Mehta Hiren R et al. IRJP 2011, 2 (12), 132-138 INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN 2230 – 8407 Available online www.irjponline.com Review Article NEW INSIGHTS INTO MOLECULAR TARGETS FOR DEPRESSION Mehta Hiren R1*, Prakash B. Thakkar2, Vishal R. Vekariya3, Indermeet Singh Anand4 1Gujarat Technological University, Ahmedabad, India 2Shri Sarvajanik Pharmacy College, Mehsana-384001, Gujarat, India 3National Institute of Pharmaceutical Education and Research (NIPER), Guwahati-781032, Assam, India 4 Professor and HOD of Pharmacology, Shri Sarvajanik Pharmacy College, Mehsana - 384001, Gujarat, India Article Received on: 19/10/11 Revised on: 20/11/11 Approved for publication: 17/12/11 *E-mail: [email protected] ABSTRACT Major depressive disorder is a heritable neuropsychiatric syndrome characterized by relatively subtle cellular and molecular alterations localized to a complex network of neural substrates. Various forms of psychotherapy, pharmacotherapy, and electroconvulsive therapy (ECT) are currently the most commonly used antidepressant treatments. Despite adequate care with currently available treatments, up to 70% of depressed patients have residual symptoms, and, even with more aggressive therapies, 20% or more may show only a limited response. The need for newer compounds to treat depression is still an ever growing concern due to the enormous societal and famifications of depression. This review covers all the monoaminergic (SSRI/5-HT1A antagonists, SSRI/5-HT2C antagonists, SSRI/alpha-2 adrenergic antagonists, triple reuptake inhibitors, dopamine agonists, targeting GABA) and beyond monoaminergic strategies including corticotropin-releasing factor (CRF)-1 receptor antagonists, Inhibition of glucocorticoid function, substance P (Nk-1) antagonists, MCH1 receptor antagonists, Gal3 receptor antagonists, arginine vasopressin as the potential novel targets for depression.
    [Show full text]
  • Partial Agonism and Schizophrenia Modest Success
    BRITISH JOURNAL OF PSYCHIATRY (2005), 186, 7^10 EDITORIAL Partial agonism and schizophrenia modest success. It is apparent, though, that all effective antipsychotics to date incorpo- rate D2 receptor antagonism in their A. A. BOLONNA and R. W. KERWIN mechanism of action; therefore, the current drug discovery process aims to identify drugs that primarily target the dopaminer- gic system with greater therapeutic efficacy (Kapur & Mamo, 2003). When considering the potential benefits of dopamine receptor partial agonists in the treatment of schizo- phrenia, two functional aspects of the dopaminergic system require consideration: Recent literature on partial agonists has intrinsic activity than full agonists. Partial the postulated reciprocal dysregulation of generated interest in their therapeutic agonists can elicit different receptor re- cortical and subcortical dopamine systems, potential in schizophrenia. This has been sponses depending on their environment: and the role of dopamine autoreceptors in driven, in part, by the recent approval of in the presence of agonists with higher schizophrenia. the dopamine (D2) receptor partial agonist intrinsic activity, partial agonists can aripiprazole in the USA and Europe. In demonstrate antagonist properties by comparison with conventional and atypical blocking access to the receptor, but on their DUAL PATHOLOGY antipsychotics that mediate their therapeu- own they will act as agonists (Fig. 1). tic effects by D2 receptor blockade, aripi- There are numerous reports of partial ago- The original dopamine hypothesis for prazole has a unique mechanism of action. nists that act at the D2 receptor; those of re- schizophrenia was based on the belief that However, the concept of partial agonists levance to the treatment of schizophrenia dopamine only innervated subcortical for the treatment of schizophrenia is not are discussed in detail below.
    [Show full text]
  • Pharmacotherapy for Stimulant Use Disorders: a Systematic Review
    4 D epartment of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Pharmacotherapy for Stimulant Use Disorders: A Systematic Review August 2018 Prepared for: Investigators: Department of Veterans Affairs Principal Investigator: Veterans Health Administration Brian Chan, MD, MPH Quality Enhancement Research Initiative Co-Investigators: Health Services Research & Development Service Karli Kondo, PhD, MA Washington, DC 20420 Chelsea Ayers, BA Prepared by: Michele Freeman, MPH Jessica Montgomery, MPH Evidence-based Synthesis Program (ESP) Robin Paynter, MLIS Portland VA Health Care System Devan Kansagara, MD, MCR Portland, OR Devan Kansagara, MD, MCR, Director 4 Pharmacotherapy for Stimulant Use Disorders Evidence-based Synthesis Program PREFACE The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for 4 ESP Centers, and each Center has an active University affiliation. Center Directors are recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Centers. The ESP is governed by a Steering Committee comprised of participants from VHA Policy, Program, and Operations Offices, VISN leadership, field-based investigators, and others as designated appropriate by QUERI/HSR&D. The ESP Centers generate evidence syntheses on important clinical practice topics. These reports help: · Develop clinical policies informed by evidence; · Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and · Set the direction for future research to address gaps in clinical knowledge.
    [Show full text]
  • Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion
    J. Membrane Biol. 165, 201–211 (1998) The Journal of Membrane Biology © Springer-Verlag New York Inc. 1998 Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion H. Fischer1, R. Gottschlich2, A. Seelig1 1Department of Biophysical Chemistry, Biocenter of the University of Basel, Klingelbergstr, 70, CH-4056 Basel, Switzerland 2Medicinal Chemistry Research Laboratories, CNS Department, E. Merck, Frankfurter Strasse 250, 64271 Darmstadt, Germany Received: 7 April 1998/Revised: 25 June 1998 Abstract. 53 compounds with clinically established abil- Introduction ity to cross or not to cross the blood-brain barrier by passive diffusion were characterized by means of surface Passive diffusion through the blood-brain barrier (BBB) activity measurements in terms of three parameters, i.e., is the primary process of translocation from the blood the air-water partition coefficient, Kaw, the critical mi- stream to the brain for the large majority of therapeutic celle concentration, CMCD, and the cross-sectional area, compounds. On a morphological level, the BBB consists AD. A three-dimensional plot in which the surface area, of the brain microvascular endothelium cells coupled by −1 AD, is plotted as a function of Kaw and CMCD shows tight junctions. On a molecular level, the principal dif- essentially three groups of compounds: (i) very hydro- fusion barrier consists of the lipid bilayer. The latter is a phobic compounds with large air-water partition coeffi- highly anisotropic system which can be divided into at 2 cients and large cross-sectional areas, AD > 80 Å which least two distinct regions: (i) the polar head group-water do not cross the blood-brain barrier, (ii) compounds with interface region, and (ii) the nonpolar hydrocarbon re- lower air-water partition coefficients and an average gion.
    [Show full text]
  • Involvement of Dopamine D2 and 5-HT IA Receptors in Roxindole-Induced Antinociception
    Indi an Journal of Experiment al Biology Vol. 37, March 1999, pp. 23 4-237 Involvement of dopamine D2 and 5-HT IA receptors in roxindole-induced antinociception Ipe Ninan & S K Kulkarni* Ph armaco logy Di vision, Universit y In stitute of Pharmaceutical Sciences, Panj ab Uni versity, Chand igarh )60014, Indi a Received 23 March 1998; revi sed 27 November 1998 Rox i Il dole. a DA O2 receptor ago ni st (2-1 6 mglkg) produ ced dose-dependent i ncrease in percent age <I ntinociceptio nT he effect whi ch was bl ocked by DA O2 antago ni st (-)s ulpiride (50 mglkg) and 5-HTIAr eceptor antagoni st (-) pin do lol (5 mg/kgl. Rox in do le (4 and 8 mglkg) reversed both nalo xo ne (20 mglkg)-induced hyperalgesia and reserpine (2 mg/kg)-i nduced hyperalgesia. Th is reversal was sensiti ve to blockade by both (-)su lpiri cte (50 mglkg) and (-) pindolol (5 mg/kg). The presen t stud y s~ges t s th at ro xindol e-induced ant inocicepti on is mediated by postsynaptic DA D2 and 5-HTIA rece pt ors. Rox indole (EMD 49980) is a representati ve of a new severe pain associated with various states of di sease class of dopaminergic drugs, I. e., the indolyl affecting the nervous system, such as. the thalamic butylamines. whi ch lac k structural similarities with syndrome, herpes zoster and Parkinson's either ri gid dopamine (DA ) analogs or ergot di sease' 1.l 2.'J.'4. and a recent study showed that 8-0H deri vatives '.
    [Show full text]
  • New Information of Dopaminergic Agents Based on Quantum Chemistry Calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A
    www.nature.com/scientificreports OPEN New information of dopaminergic agents based on quantum chemistry calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A. Ibarra3, Rubicelia Vargas4, Elisabeth Winnberg5 & Ana Martínez6* Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease. Antipsychotics are drugs that interact primarily with the dopamine receptors and are thus important for the control of psychosis and related disorders. These drugs function as agonists or antagonists and are classifed as such in the literature. However, there is still much to learn about the underlying mechanism of action of these drugs. The goal of this investigation is to analyze the intrinsic chemical reactivity, more specifcally, the electron donor–acceptor capacity of 217 molecules used as dopaminergic substances, particularly focusing on drugs used to treat psychosis. We analyzed 86 molecules categorized as agonists and 131 molecules classifed as antagonists, applying Density Functional Theory calculations. Results show that most of the agonists are electron donors, as is dopamine, whereas most of the antagonists are electron acceptors. Therefore, a new characterization based on the electron transfer capacity is proposed in this study. This new classifcation can guide the clinical decision‑making process based on the physiopathological knowledge of the dopaminergic diseases. During the second half of the last century, a movement referred to as the third revolution in psychiatry emerged, directly related to the development of new antipsychotic drugs for the treatment of psychosis.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,560,544 B2 Webber Et Al
    USOO756.0544B2 (12) United States Patent (10) Patent No.: US 7,560,544 B2 Webber et al. (45) Date of Patent: Jul. 14, 2009 (54) 3.5-DISUBSITITUTED AND 2003.01.00764 A1 5/2003 Bonket al. 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 2003,01628.06 A1 8, 2003 Dellaria et al. 3H-THIAZOLO4,5-DIPYRIMIDIN-2-ONE 2003/0176458 A1 9, 2003 Dellaria et al. COMPOUNDS AND PRODRUGS THEREOF 2003/0186949 A1 10, 2003 Dellaria et al. 2003. O195209 A1 10, 2003 Dellaria et al. (75) Inventors: Stephen E. Webber, San Diego, CA S-8. A. 1929 St.oberts etet al. al. (US); Gregory J. Haley, Del Mar, CA 2005, 0004144 A1 1/2005 Carson et al. (US); Joseph R. Lennox, San Diego, CA (US); Alan X. Xiang, San Diego, CA FOREIGN PATENT DOCUMENTS (US); Erik J. Rueden, Santee, CA (US) EP O 882 727 9, 1998 EP 1 035 123 9, 2000 (73) Assignee: Anadys Pharmaceuticals, Inc., San EP 1043 021 10, 2000 Diego, CA (US) EP 1386,923 A1 2, 2004 WO WO-89/05649 6, 1989 Notice: Subject to any disclaimer, the term of this WO WO-92, 16215 10, 1992 (*) WO WO-94,07904 4f1994 patent is extended or adjusted under 35 WO WO-94, 17043 8, 1994 U.S.C. 154(b) by 119 days. WO WO-94.17090 8, 1994 WO WO-98, 17279 4f1998 (21) Appl. No.: 11/304,691 WO WO-03/045968 6, 2003 (22) Filed: Dec. 16, 2005 OTHER PUBLICATIONS Vippagunta et al. Advanced Drug Delivery Reviews 48 (2001)3-26.* (65) Prior Publication Data Lugemwaetal.
    [Show full text]
  • Biomedical Importance of Indoles
    Molecules 2013, 18, 6620-6662; doi:10.3390/molecules18066620 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Biomedical Importance of Indoles Nagendra Kumar Kaushik 1,*, Neha Kaushik 1,*, Pankaj Attri 1, Naresh Kumar 1, Chung Hyeok Kim 1, Akhilesh Kumar Verma 2,* and Eun Ha Choi 1,* 1 Plasma Bioscience Research Center, Kwangwoon University, Seoul 139701, Korea; E-Mails: [email protected] (P.A.); [email protected] (N.K.); [email protected] (C.H.K.) 2 Department of Chemistry, University of Delhi, Delhi 110007, India * Authors to whom correspondence should be addressed; E-Mails: [email protected] (N.K.K); [email protected] (N.K.); [email protected] (A.K.V.); [email protected] (E.H.C.); Tel.: +82-10-4187-8618 (N.K.K.) Fax: +82-940-5664 (N.K.K). Received: 17 April 2013; in revised form: 27 May 2013 / Accepted: 28 May 2013 / Published: 6 June 2013 Abstract: The indole nucleus is an important element of many natural and synthetic molecules with significant biological activity. This review covers some of the relevant and recent achievements in the biological, chemical and pharmacological activity of important indole derivatives in the areas of drug discovery and analysis. Keywords: indole; biomedical application; bioactivity; pharmacological activity 1. Introduction Heterocyclic chemistry is one of the most valuable sources of novel compounds with diverse biological activity, mainly because of the unique ability of the resulting compounds to mimic the structure of peptides and to bind reversibly to proteins [1–4]. To medicinal chemists, the true utility of heterocyclic structures is the ability to synthesize one library based on one core scaffold and to screen it against a variety of different receptors, yielding several active compounds.
    [Show full text]